Epigenetics Drugs and Diagnostic Technologies Market Report 2024

This Epigenetics Drugs And Diagnostic Technologies market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The epigenetics drugs and diagnostic technologies market size has grown exponentially in recent years. It will grow from $12.78 billion in 2023 to $15.49 billion in 2024 at a compound annual growth rate (CAGR) of 21.2%. The growth during the historic period can be attributed to a deeper understanding of epigenetic mechanisms, the advancement of genome-wide association studies (GWAS), rising healthcare demands, an increasing geriatric population, and a higher prevalence of cancer.

The epigenetics drugs and diagnostic technologies market size is expected to see exponential growth in the next few years. It will grow to $33.82 billion in 2028 at a compound annual growth rate (CAGR) of 21.6%. The anticipated growth during the forecast period can be attributed to several factors, including the increasing prevalence of neurological diseases, a rising incidence of inflammatory disorders, growing rates of chronic diseases, heightened demand for personalized medicine, and greater awareness and adoption of epigenetic diagnostics. Key trends for the forecast period include advancements in epigenetic-based personalized therapies, the integration of epigenomics with artificial intelligence, innovations in multi-omics approaches for research and clinical practice, the development of advanced technologies, and new diagnostic techniques.

The rising prevalence of cancer is expected to drive the growth of the epigenetics drugs and diagnostic technologies market. Cancer encompasses a range of diseases characterized by abnormal cell growth that can invade or spread to other parts of the body. This increasing prevalence is influenced by factors such as aging populations, lifestyle changes, environmental pollutants, genetic predispositions, and advancements in diagnostic techniques. Epigenetic drugs and diagnostic technologies play a crucial role in addressing the rising incidence of cancer by targeting and modifying gene expression, facilitating early detection, and enabling personalized treatment approaches. For example, in July 2024, the Australian Institute of Health and Welfare, an Australian government agency, reported that the number of cancer cases diagnosed in Australia rose from 156,781 in 2021 to 160,570 in 2022. Consequently, the growing prevalence of cancer is driving the expansion of the epigenetics drugs and diagnostic technologies market.

Major companies in the epigenetics drugs and diagnostic technologies market are concentrating on creating innovative technologies, such as DNA methylation analysis, to boost the precision and effectiveness of disease detection, refine personalized treatment strategies, and deepen our understanding of gene regulation across various diseases. DNA methylation analysis involves studying the patterns of DNA methylation, which is a chemical modification where a methyl group is added to the cytosine base of DNA. For example, in August 2023, Watchmaker Genomics Inc., a US-based biotechnology firm, teamed up with Exact Sciences Corp., a US-based molecular diagnostics company, to develop and commercialize a novel DNA methylation analysis technology called TET-assisted pyridine borane sequencing (TAPS). This partnership aims to improve cancer screening and diagnostic capabilities by utilizing Watchmaker's expertise in engineering DNA-modifying enzymes to enhance TAPS chemistry. This collaboration is crucial for early cancer detection and monitoring minimal residual disease (MRD) through liquid biopsies, where DNA methylation patterns act as biomarkers for health status.

In January 2022, Active Motif Incorporated, a US-based firm specializing in epigenetics and chromatin biology, acquired Amaryllis Nucleics for an undisclosed sum. This acquisition enables Active Motif to provide a more integrated approach to gene expression analysis by combining their expertise in chromatin biology and epigenetics with Amaryllis Nucleics' RNASeq technology. Amaryllis Nucleics, also based in the US, specializes in epigenetics drugs and diagnostic technologies.

Major companies operating in the epigenetics drugs and diagnostic technologies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Illumina Inc., QIAGEN NV, Exact Sciences Corporation, Abcam PLC, Syndax Pharmaceuticals Inc., Astex Pharmaceuticals Inc., Diagenode LLC, Cisbio Bioassays, 4SC AG, Verogen Inc., Watchmaker Genomics Inc., Oryzon Genomics SA, Cell Centric Ltd., Epiaxis Therapeutics.

North America was the largest region in the epigenetics drugs and diagnostic technologies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epigenetics drugs and diagnostic technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the epigenetics drugs and diagnostic technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Epigenetics drugs and diagnostic technologies refer to therapeutic and diagnostic approaches that target and analyze the epigenetic mechanisms regulating gene expression without altering the underlying DNA sequence. These technologies are focused on modifying or assessing the chemical modifications to DNA and histones that influence gene activity, offering potential treatments for various diseases and advanced diagnostic tools.

The main technologies of epigenetics drugs and diagnostic technologies are deoxyribonucleic acid (DNA) methylation, histone methylation, histone acetylation, large noncoding ribonucleic acid (RNA), microRNA modification, chromatin structures. Deoxyribonucleic acid (DNA) methylation involves adding a methyl group to the DNA molecule, typically at cytosine bases. These are used in various applications such as oncology, solid tumors, liquid tumors, nononcology, inflammatory diseases, metabolic diseases, infectious diseases, cardiovascular diseases, and others, and also by various end-users such as hospitals and clinics, diagnostic centers, and others.

The epigenetics drugs and diagnostic technologies market research report is one of a series of new reports that provides epigenetics drugs and diagnostic technologies market statistics, including epigenetics drugs and diagnostic technologies industry global market size, regional shares, competitors with an epigenetics drugs and diagnostic technologies market share, detailed epigenetics drugs and diagnostic technologies market segments, market trends, and opportunities, and any further data you may need to thrive in the epigenetics drugs and diagnostic technologies industry. This epigenetics drugs and diagnostic technology research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epigenetics drugs and diagnostic technologies market consists of revenues earned by entities by providing DNA methylation analysis, histone modification detection, non-coding RNA profiling, epigenetic biomarker discovery, and single-cell epigenomics. The epigenetics drugs and diagnostic technologies market also includes sales of histone deacetylase inhibitors, RNA-based drugs, chromatin remodeling agents and bromodomain inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.